Is there clinical value to prognostic signatures in early-stage NSCLC?

Clin Cancer Res. 2014 Apr 1;20(7):1727-9. doi: 10.1158/1078-0432.CCR-13-3387. Epub 2014 Feb 28.

Abstract

pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Humans
  • Neoplasm Staging
  • Phosphorylation
  • Precision Medicine
  • Predictive Value of Tests
  • Prognosis*
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • AMP-Activated Protein Kinases